University of Caen-Normandie
Also known as: Anesthesiologist | Baclesse, Caen, France | Caen (FR), University College Hospital | Caen Hospital | Caen University Hospital, Normandie UNIV, UNICAEN, PSL Research University, EPHE, Inserm, U1077, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, 14000 Caen, France | Centre François Baclesse | Centre Francois Baclesse | Centre François Baclesse | Centre Francois Baclesse-CAEN | Centre François Baclesse, Caen, France | Centre Francois Baclesse, Luxembourg | Centre Hospitalier Universitaire CAEN | Centre Hospitalier universitaire de Caen | Centre Hospitalier Universitaire de Caen Normandie | CHRU Caen | CHRU de Caen | CHU caen | CHU Caen | CHU CAEN | CHU Cote de Nacre, Caen, France | Endocrinology Unit, University Hospital of Caen, FRANCE | GELA - CHU de Caen, Caen, FR | Hopital Cote de Nacre, Caen | Hopital Cote de Nacre CAEN France | HOSPITAL, CAEN | Université de Caen Normandie | University Hospital, Caen | University hospital of Caen | University Hospital of Caen | Universtiy Hospital of Caen
Highest phase reached
Phase 4
First clinical trial
May 1, 2003Last known activity
Oct 1, 2025
Timeline
1430s
- Jun 1, 1432
University of Caen-Normandie— Founded
Drugs by trial phase (130 distinct, 105 trials)
Phase 4 (16 own, 0 via acquisition)
Phase 3 (49 own, 0 via acquisition)
Phase 2 (43 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Other trials (16 own, 0 via acquisition)
Indications
Studied for
- Acute Kidney Injury
- Adenocarcinoma
- Adenoma
- Anemia, Iron-Deficiency
- Anus Neoplasms
- Arteritis
- Arthritis
- Arthritis, Rheumatoid
- Atrial Fibrillation
- Breast Neoplasms
- Carcinoma
- Carcinoma, Merkel Cell
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Ovarian Epithelial
- Carotid Stenosis
- Chondrocalcinosis
- Cognition Disorders
- Crush Injuries
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diarrhea
- Dyslipidemias
- Esophageal Neoplasms
- Facial Paralysis
- Facies
- Giant Cell Arteritis
- Glioma
- Graft vs Host Disease
- Head and Neck Neoplasms
- Hemorrhage
- Hodgkin Disease
- Hypercholesterolemia
- Hyperparathyroidism
- Hypogonadism
- Immunologic Deficiency Syndromes
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Medulloblastoma
- Melanoma
- Meningeal Carcinomatosis
- Meningitis
- Mesothelioma
- Multiple Myeloma
- Multiple Sclerosis
- Muscular Dystrophies
- Muscular Dystrophy, Oculopharyngeal
- Nausea
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Neutropenia
- Obesity, Morbid
- Osteoporosis
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Parathyroid Neoplasms
- Paresis
- Parkinson Disease
- Polycystic Ovary Syndrome
- Polymyalgia Rheumatica
- Postpartum Hemorrhage
- Prolapse
- Prostatic Neoplasms
- Recurrence
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Retinal Neoplasms
- Retinoblastoma
- Sarcoma
- Sclerosis
- Shock
- Shock, Septic
- Stomach Neoplasms
- Stroke
- Subarachnoid Hemorrhage
- Syndrome
- Telangiectasia, Hereditary Hemorrhagic
- Telangiectasis
- Uterine Cervical Neoplasms
- Vomiting
Recent trials (50)
- NCT07028125Lead sponsorPhase 4Oct 1, 2025
- NCT06263816CollaboratorPhase 3Nov 15, 2024
- NCT06642844CollaboratorPhase 3Oct 30, 2024
- NCT06518317Lead sponsorPhase 3Sep 30, 2024
- NCT06495723OfficialPhase 1/Phase 2Jul 9, 2024
- NCT06204640Lead sponsorPhase 3Mar 1, 2024
- NCT06034938Lead sponsorPhase 2Dec 1, 2023
- NCT06062134Overall official - principal investigatorN/AMay 15, 2023
- NCT05699005CollaboratorPhase 1Feb 28, 2023
- NCT05241405Lead sponsorN/ASep 27, 2022
- NCT05201547Overall official - principal investigatorPhase 3Apr 15, 2022
- NCT04927949Lead sponsorPhase 4Jun 8, 2021
- NCT04920448Lead sponsorPhase 2Jun 7, 2021
- NCT04678362Lead sponsorPhase 2Jun 1, 2021
- NCT04879290Study directorN/AApr 9, 2021
Details
- Founded
- Caen, FR Jun 1, 1432
- Last known activity
- Oct 1, 2025